* Ardelyx Inc reported a quarterly adjusted loss of 11 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of -13 cents. The mean expectation of ten analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -25 cents to -12 cents per share.
* Revenue rose 304.8% to $46.02 million from a year ago; analysts expected $36.40 million.
* Ardelyx Inc's reported EPS for the quarter was a loss of 11 cents.
* The company reported a quarterly loss of $26.52 million.
* Ardelyx Inc shares had fallen by 9.5% this quarter and gained 6.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 38.7% in the last three months.
* In the last 30 days, three analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"
Wall Street's median 12-month price target for Ardelyx Inc is $13.50 This summary was machine generated from LSEG data May 2 at 09:54 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.15 -0.11 Beat
Dec. 31 2023 -0.09 -0.12 Missed
Sep. 30 2023 -0.11 0.03 Beat
Jun. 30 2023 -0.11 -0.08 Beat
Comments